Molecules that protect brain cells from Parkinson`s identified
Whitehead Institute researchers claim to have identified small molecules that appear to be capable of protecting brain cells from alpha-synuclein toxicity, a hallmark of Parkinson`s disease.
|Last Updated: Dec 29, 2009, 12:00 AM IST|Source: Bureau
Washington: Whitehead Institute researchers claim to have identified small molecules that appear to be capable of protecting brain cells from alpha-synuclein toxicity, a hallmark of Parkinson`s disease.During the study, the team came across four related small molecules that prevented the development of several cellular traits associated with Parkinson``s disease, including the accumulation of alpha-synuclein deposits in the cell, improper protein trafficking from one organelle to another, and damage inflicted on the cells`` engines, the mitochondria.
"In this research, we used yeast as a Parkinson`s disease model system to identify the compounds that really work in two higher order model systems of Parkinson``s," said Julie Su, a first co-author on the paper describing the research and a former postdoctoral researcher in Whitehead Member Susan Lindquist``s lab.
The yeast was modified to produce too much of the alpha-synuclein protein in its cells. The resulting cells manifest adverse effects similar to those experienced in brain cells from Parkinson``s patients.
Using this yeast strain, the Lindquist team screened 115,000 small compounds to see which ones alleviate the Parkinson``s-like traits. During a screen, a compound is added to a small amount of yeast
Four compounds were found to restore the alpha-synuclein yeast cells`` growth to 50pc of normal yeast cells. Yeast cells that were not treated with the compounds died.
The researchers also identified two commercially available compounds with similar chemical structures and used those in further tests. In the study conducted using round worm Caenorhabditis elegans and rat neurons, the first four compounds were able to rescue the round worms, while in the rat neurons, three of the four original compounds and one of the commercial compounds improved the nerve cells`` growth.
"Those two things are obviously related," said Pavan Auluck, first co-author and a visiting scientist in the Lindquist lab.
"We``re trying to figure out what the connections are between them. And there are a number of ways they can be related," Auluck added.
"There are very deeply rooted processes that connect protein trafficking and mitochondrial viability," said Lindquist, who is also a Howard Hughes Medical Institute investigator and a professor of biology at MIT. "That emphasizes that the underlying problem caused by alpha-synuclein is a general cellular defect that is part of the machinery of all eukaryotic cells. The specific problems in Parkinson``s are due to the neurons being particularly sensitive to that process going awry."
The study appears in Disease Models and Mechanisms (DMM).
ANI
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookies Setting
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device and the processing of information obtained via those cookies (including about your preferences, device and online activity) by us and our commercial partners to enhance site navigation, personalise ads, analyze site usage, and assist in our marketing efforts. More information can be found in our Cookies and Privacy Policy. You can amend your cookie settings to reject non-essential cookies by clicking Cookie Settings below.
Manage Consent Preferences
Strictly Necessary Cookies
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work or you may not be able to login.
Functional Cookies
These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.
Targeting Cookies
These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They are also used to limit the number of times you see an advert as well as help measure the effectiveness of an advertising campaign. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.
Performance Cookies
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we may not know when you have visited our site, and may not be able to monitor its performance.